Loading Events

« All Events

  • This event has passed.

State Access to Unapproved Drugs: A Moderated Conversation

October 20 @ 10:00 am – 11:00 am EDT

Join 1Day Sooner on October 20 at 10:00 AM ET for a moderated conversation on state-sanctioned right-to-try laws with Holly Fernandez Lynch (University of Pennsylvania) and Niklas Anzinger (Infinita).

Through regulations finalized in 2026, Montana has built a pathway that lets biotech companies sell experimental drugs that have completed early-stage testing equivalent to a phase-1 trial directly to consumers. These products can be provided through Experimental Treatment Centers so long as a private Experimental Treatment Review Board has signed off after a review of safety and informed consent. Unlike the federal Right to Try law and FDA’s Expanded Access pathway, there is no constraint on patient eligibility and no restriction on price or profit. Montana’s law extends access to anyone who gives informed consent and can pay for the experimental treatments (if required), which may include patients with rare diseases, neurodegenerative diseases or cancer, or healthy people seeking access to preventive interventions or longevity products.
Supporters see a responsible route for people who wish to exercise medical freedom and who have been unable to access unapproved products through clinical trials or the federal right-to-try or expanded-access pathways. Critics raise serious concerns, noting that early-phase studies do not establish a drug’s safety for patient use and arguing that profiting from unproven products without FDA oversight creates a risk of both physical harm and exploitation.
Join us for a moderated conversation that will explore:

● The federal right-to-try and expanded access pathways and their strengths and limitations;
● Why so many patients cannot meet clinical trial eligibility criteria, and what that means for their access to experimental interventions;
● Regulatory and ethical considerations for collecting real-world data from people who purchase experimental products;
● Broader ethical considerations raised by state-sanctioned right-to-try clinics; [1] [HF2]
● How the Experimental Treatment Review Board (ETRB) compares to an Institutional Review Board (IRB), and whether an ETRB gives consumers of experimental products protections similar to those afforded to participants in clinical research[HF3] ; and
● Much more!

Our guests:

Holly Fernandez Lynch, JD, MBe is Associate Professor of Medical Ethics & Health Policy and Associate Professor of Law (secondary) at the University of Pennsylvania.
Niklas Anzinger is the founder of Infinita and helped draft Montana’s 2025 law establishing experimental treatment clinics.